Tov Sperco Ukraine

Sperco Ukraine LLC is engaged in manufacturing high-quality medicinal products, focusing on various medical fields such as pediatrics, dermatology, gynecology, and general therapy, thereby enhancing healthcare accessibility and treatment efficacy. Founded in 1997 and headquartered in Vinnytsia, Ukraine, Sperco Ukraine LLC specializes in producing medicinal products for a diverse range of medical fields. In November 2012, the company underwent a significant change when Lux Pharma Participations S. A.

acquired a 95% majority stake, completing the transaction in January 2013. Sperco Ukraine specializes in the manufacture of high-quality medicinal products, catering to various medical fields including pediatrics, dermatology, gynecology, and general therapy. Their core offerings aim to improve treatment accessibility and efficacy for a diverse range of medical conditions, making them valuable assets in healthcare practices. The company's focus on quality is underscored by their commitment to Spanish standards, which they combine with competitive Ukrainian pricing.

Their products are designed to support healthcare professionals by providing reliable and effective treatment options, thereby enhancing patient care outcomes. Sperco products are primarily distributed within Ukraine, serving hospitals, clinics, and pharmacies, as well as directly impacting patients who rely on their medications for treatment. Sperco Ukraine's revenue model is structured around direct sales of pharmaceutical products to healthcare providers, pharmacies, and hospitals. In 2020, the company reported a revenue of USD 25.

81 mn and an EBITDA of USD 8. 09 mn. Transactions typically occur through wholesale partnerships, where Sperco engages with retailers and distributors, ensuring their products reach end-users efficiently. The pricing structure reflects the company’s commitment to affordability while maintaining high quality, with flagship products being integral to their portfolio.

The company focuses on building long-term relationships with its clients, which facilitates consistent revenue streams through regular orders and replenishment of stock. Through strategic partnerships and a well-defined distribution network, Sperco successfully integrates its products into the healthcare market, thereby ensuring a steady flow of transactions that support its operational growth. Sperco Ukraine plans to launch several new medicinal products aimed at expanding its therapeutic offerings. The company is targeting expansion into Eastern European markets by the end of 2023, seeking to enhance its market presence.

The proceeds from the acquisition by Lux Pharma Participations S. A. in November 2012 are expected to support these initiatives, aiding in product development and market entry strategies.